IBO:CC - Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors
(TheNewswire)
Calgary, AB – TheNewswire - April 21, 2022 – Universal Ibogaine Inc.( TSXV:IBO ) (“ UI ” or the “ Company ”) a life sciences company with amission to develop and deliver medicalized ibogaine-centered addictioncare, advises that Marilyn Loewen Mauritz has resigned as a member ofthe UI Board of Directors to pursue other opportunities.
The Board of Directors would like to thank Marilyn forher significant contribution to the Company during her tenure as aDirector and wish her well in her future endeavours.
About Universal Ibogaine Inc.
UI is a life sciences company, with amission to demonstrate the safety and efficacy of its ibogaine baseddrug detox protocol through a planned Canadian Clinical Trial (focusedon opioid use disorder), and ultimately to utilize that protocolaround the globe through planned future licensing agreements. UI isconcurrently developing a state of the art holistic addictiontreatment protocol at its Kelburn Recovery Centre that, when pairedwith the planned ibogaine detox protocol, is intended to revolutionizethe way we treat addiction and drastically improve the lives ofindividuals and families affected by addiction.
NEITHER THE TSX VENTURE EXCHANGE NORITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THEPOLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THEADEQUACY OR ACCURACY OF THIS RELEASE.
CAUTIONARY STATEMENT REGARDINGFORWARD-LOOKING STATEMENTS
?This news release may contain forward-lookingstatements and information. Forward-looking information is frequentlycharacterized by words such ?as "plans","expect", "project", "intend","will", "believe", "anticipate","estimate", "scheduled",??"potential", or other similar words, or statementsthat certain events or conditions "may", "should"or ??"could" occur. The forward-looking statements andinformation are based on certain key expectations ?and assumptionsmade by UI. Although UI believes that the expectations andassumptions on which the forward-?looking statements are based arereasonable, undue reliance should not be placed on theforward-?looking statements because UI can give no assurance thatthey will prove to be correct.
Since ?forward-looking statements address futureevents and conditions, by their very nature they involve ?inherentrisks and uncertainties. Actual results could differ materially fromthose currently anticipated ?due to a number of factors and risks,which include, but are not limited to, risks that required?regulatory approvals are not obtained. The reader is cautioned thatassumptions used in the ?preparation of such information, althoughconsidered reasonable by UI at the time of ?preparation, may proveto be incorrect and readers are cautioned not to place undue relianceon ?forward-looking information, which speaks only to conditions asof the date hereof. UI does not ?undertake any obligation torelease publicly any revisions to forward-looking informationcontained ?herein to reflect events or circumstances that occurafter the date hereof or to reflect the occurrence ?of unanticipatedevents, except as may be required under applicable securities laws.?
For further information:
Investor Relations: Dugan Selkirk, IR Manager
dugan.selkirk@universalibogaine.com
Copyright (c) 2022 TheNewswire - All rights reserved.